Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reducing Frailty for Older Cancer Survivors Using Supplements
Sponsor: University of Rochester
Summary
The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer
Official title: Reducing Frailty for Older Cancer Survivors Using Supplements (ReFOCUS): A Pilot Randomized Controlled Trial of the Feasibility, Safety, and Preliminary Effects of Epigallocatechin-3-Gallate (EGCG) in Pre-Frail and Frail Older Cancer Survivors
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2021-04-28
Completion Date
2023-08-31
Last Updated
2026-05-07
Healthy Volunteers
No
Conditions
Interventions
Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)
800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
Locations (1)
University of Rochester
Rochester, New York, United States